Amersham Articles
European And London Stock Comment
19 June 1997
Amersham Pharmacia Biotech Unveiled
11 June 1997
European And London Stock Comment
9 June 1997
Amersham Int Confirms In Talks With P&U
9 June 1997
European And London Stock Comment
21 April 1997
The Future Of Genomics At SmithKline Beecham
10 March 1997
Acquisitions And Mergers Continue, Led By Novartis
6 January 1997
Stock Commentary: Europe
9 December 1996
EUROPEAN AND LONDON STOCK COMMENT
25 November 1996
Amersham Up On Myoview and Overseas
18 November 1996
Amersham International's Myoview Approved In Japan
14 October 1996
Appointment At Amersham International
17 June 1996
Currency, Life Sciences Boost Amersham Results
17 June 1996
Amersham Ups Stake In Nihon
6 May 1996
Non-executive Appointment At Amersham International
22 April 1996
Improving Fundamentals At Amersham Int'l
22 April 1996
Towards Effective Diagnosis Of Alzheimer's Disease
1 April 1996
Stock Comment - Europe
26 February 1996
EUROPE STOCK COMMENT
19 February 1996
Amersham's Myoview Gets FDA Go-Ahead
19 February 1996
EUROPEAN STOCK COMMENT
13 November 1995
Amersham Looks Forward To The Future
13 November 1995
EUROPEAN STOCK COMMENT
18 September 1995
Amersham International appointment
4 September 1995
EUROPEAN STOCK COMMENT
7 August 1995
European STOCK COMMENT
24 July 1995
Good And Bad News From Amersham
24 July 1995
EUROPEAN STOCK COMMENT
3 July 1995
EUROPEAN STOCK COMMENT
26 June 1995
Amersham's Growth Slows To 9%
12 June 1995
The ABPI's A-Z Of British Medicines Research
29 May 1995
European Stock Comment
17 April 1995
Amersham's Stabilized Ceretec Approved
17 April 1995
Corporate News In Brief
10 April 1995
European Stock Comment
13 February 1995
Oligopoly The Future For The Pharma Industry
2 January 1995
European Stock Comment
21 November 1994
EUROPEAN STOCK COMMENT
14 November 1994
Amersham's 1st Half Disappoints But Strategy Good
14 November 1994
European STOCK COMMENT
24 October 1994
Amersham Bio-Imaging Agreement
17 October 1994
Amersham Plugs Japan Gap With Key Alliance
17 October 1994
Louis Da Gamma Joins Amersham
3 October 1994
UK Press Coverage Of Drug Firms
19 September 1994
AMERSHAM RUSSIAN DEAL
1 August 1994
New UK Trials For Amersham's Ceretec
18 July 1994
EUROPEAN STOCK COMMENT
20 June 1994
MYOVIEW LAUNCH IN UK
13 June 1994
EUROPE STOCK COMMENT
13 June 1994
AMERSHAM'S GOOD RESULTS BOOSTED BY USB
13 June 1994
MEDI-PHYSICS LAUNCH
23 May 1994
AMERSHAM IN US/JAPAN SEQUENCING ALLIANCE
18 April 1994
CELSIS EXECUTIVE WAS "INEFFECTUAL"
18 April 1994
EUROPEAN STOCK COMMENT
28 March 1994
AMERSHAM INTRODUCES ASSAY
14 March 1994
AMERSHAM INT'L IN SINGAPORE
14 February 1994
AMERSHAM APPOINTMENT
7 February 1994
METASTRON HAILED AS MAJOR ADVANCE
7 February 1994
EUROPEAN STOCK COMMENT
31 January 1994
MYOVIEW GAINS JAPANESE APPROVAL
31 January 1994
US BIOCHEMICAL SPEEDS PAYMENTS
24 January 1994
1992 SEES SMALLER COMPANY MERGERS
10 January 1994
UBS GAINS PATENT LICENSE
13 December 1993
HALF-YEAR PROFITS UP 71% AT AMERSHAM
15 November 1993
EUROPE STOCK COMMENT
15 November 1993
AMERSHAM'S MYOVIEW CLEARS CPMP
1 November 1993
IMMUNOMEDICS NEARS PRODUCT LAUNCH
25 October 1993
AMERSHAM INT'L JV
19 July 1993
PENDING APPLICATIONS IN US CONTINUE TO DWINDLE
19 July 1993
EUROPEAN STOCK COMMENT
28 June 1993
AMERSHAM'S METASTRON APPROVED IN USA
28 June 1993
EUROPEAN STOCK COMMENT
21 June 1993
AMERSHAM INT'L FOCUSSED AND GROWING
21 June 1993
AMERSHAM INT'L CONTINUES ADVANCES
14 June 1993
MALLINCKRODT'S OCTREOSCAN
7 June 1993
TOKYO STOCK COMMENT
7 June 1993
METASTRON REVIEWED
31 May 1993
ZENECA TO PROMOTE METASTRON
5 April 1993
AMERSHAM INT'L BUYS US BIOCHEMICAL
22 March 1993
APPOINTMENT AT AMERSHAM
22 March 1993
EUROPE STOCK COMMENT
1 March 1993
EUROPE STOCK COMMENT
25 January 1993
EUROPE STOCK COMMENT
4 January 1993
FDA YEAR-END DRUG APPROVALS ROLL-OUT
4 January 1993
UK FIRMS BOOSTED BY YEAR-END US APPROVALS
4 January 1993
BERTIN SEEKS NEW PARTNERS
3 August 1992
RESTRUCTURING IMPROVES AMERSHAM
15 June 1992
STOCK MARKET COMMENTARY: EUROPE
27 April 1992
SB WINS QUEEN'S AWARD FOR BACTROBAN
27 April 1992
SIR ARNOLD BURGEN RETIRES
20 April 1992
NEW LAB FOR AMERSHAM
9 March 1992
STOCK MARKET COMMENTARY: EUROPE
20 January 1992
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
